GilroyLab_UCL

Gilroy Lab @ UCL. Investigating the mechanisms underlying resolution of inflammation in humans 🧪

[Dr Marc George @DrMarcJGeorge1]

Absolutely delighted to share our @JACCJournals paper! In myocardial infarction specific targeting of #Interleukin6 trans-signalling with novel sgp130Fc was more efficacious than pan-antagonism (#Tocilizumab equivalent). Paves way for clinical trial. https://t.co/Ee4YeZD2Ut 1/5

[Akbar Lab @AkbarLab]

It's 5 pm on a Friday. You know what that means! 🍻

Yes, that's right, you can read this perspective on how ageing immunity could exacerbate COVID-19 in @ScienceMagazine : https://t.co/gMdBoB5BcP

@gilroylab_ucl will provide the drinks

[Norwegian PURE-3® @npure3]

@onelifemax @VirusPathways @pedrobeltrao @dlswaney @VignuzziLab @KroganLab @DoctorBou @_b_meyer @virusninja @jeanklim @verorezelj @BenjaminNilsson @kevansf @danishm20 @grosse_lab @CellCellPress @barabasi @Baric_Lab @davidasinclair @dandavis101 @GladstoneInst @foundmyfitness @JuliaB_fitness @mdpatrick @RMedzhitov @VirusesImmunity @Dmozaffarian Intriguingly, @gilroylab_ucl et al recently showed that blocking elevated #p38MAPK (in humans, using #Losmapimod) restores efferocytosis and inflammatory resolution in the elderly. #AntiAging #COVID19 https://t.co/M2Y7s5EC1Q

[Gabriele Pollara @gpollara]

Could failure to switch off inflammatory responses be the elderly's risk factor in #COVID19? 🤔
Key context is that age remains a risk factor for mortality even when adjusting for comorbidities.
Not new but saw today from @gilroylab_ucl & @AkbarLab.
https://t.co/Yz9Tk5A7sO

[Dr Emma S Chambers @Emma_S_Chambers]

My thoughts on why older people are more susceptible to severe Covid-19 disease (a thread). As we age there is chronic low grade inflammation termed ‘inflamageing’ and it is known that inflammation is detrimental to a functional immune response (1/5) https://t.co/YkmRx5D1Ux

[James moon @JccmoonMoon]

Healthcare worker Covid-19 serial asymptomatic test results over 5 weeks from Barts published today in Lancet. Big falls since lockdown. Current infection rate very low: Potential patients should feel reassured. Well done team! https://t.co/PiKNtpzfcW

[GilroyLab_UCL @gilroylab_ucl]

@uclmedsci @ucl

[GilroyLab_UCL @gilroylab_ucl]

Some members of our lab are helping out at Bart’s Hospital to create a bio-resource of healthcare worker samples to be able to study asymptomatic immunity of COVID-19. Last week the study recruited its 500th participant. Go @KarenFeehan93 @adrianeamantea @OliviaBracken1 🌈 🌈 🌈

[GilroyLab_UCL @gilroylab_ucl]

@BartsHospital

[Sian Henson @DrSianH]

Welcome to Twitter @gilroylab_ucl

[Daniel R. Goldstein @Gracedan10_99]

Delighted to collaborate with Derek Gilroy @ucl on new study @NatImmunol on a new pathway to improve #inflammation resolution with #aging in humans. Possibly a reason why older people do worse to viral infections including COVID? https://t.co/1qbT6zI4VH

[Rachel van de Merwe @rachelvdemerwe]

My/our paper is out! 🔬💉🧪So proud of this work and the team that made it what it is. Particular thanks go to fellow first author and absolute star Dr @roeldemaeyer, and the inspiring idea factory that is Prof @DerekGilroy1 @gilroylab_ucl.
@NatImmunol
https://t.co/kOv3N3yQZM

[GilroyLab_UCL @gilroylab_ucl]

Our new paper showing blocking p38 restores efferocytosis and resolution of inflammation in the elderly is out in ⁦@NatImmunol⁩ ! Congrats to everyone involved 💪🏻🧪 https://t.co/CsKKyWjM02

[Roel De Maeyer @roeldemaeyer]

Two in 1 week, still not quite sure I believe it myself! Check out what is the end result of @rachelvdemerwe and my work in the Gilroy lab published in @NatImmunol
https://t.co/B7JZWEvnUZ
Massively excited for this to be out! Is inflammageing caused by defects in efferocytosis?